In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.

College of Charleston's Kindred Hurtado examines one woman's weight-loss journey with the assistance of semaglutides.

Many people experience a serious return of appetite, cravings and weight after coming off Ozempic, and having read far too ...

Everyone faces unique obstacles when it comes to weight loss. Some roadblocks stem from past experiences with weight ...

Hyderabad: Dr Reddy's Laboratories is positioning itself to enter the lucrative GLP-1 (glucagon-like peptide-1) drug market, ...

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.